SCHEMBL9909316

SCHEMBL9909316

COc1ccc(F)c(F)c1-c1ncc(Cl)c2ccc(C(=O)O)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLG P00747 1/20 0.48
PLAU P00749 1/20 0.48
HTR5A P47898 5/20 0.47
LMNA P02545 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
CTSA P10619 1/20 0.45
TTR P02766 1/20 0.43
MRGPRX4 Q96LA9 2/20 0.41
RORC P51449 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA7 P43166 1/20 0.41
TPMT P51580 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9909312 0.90 HTR5A (0.47) PLGPLAUHTR5ARAB9ACTSA
SCHEMBL9909268 0.87 HTR5A (0.61) PLGPLAUHTR5ALMNAMAPK1
SCHEMBL9908014 0.86 HTR5A (0.54) PLGPLAUHTR5ARORCKCNQ3
SCHEMBL9909318 0.86 HTR5A (0.68) PLGPLAUHTR5ACTSA
SCHEMBL9909315 0.85 HTR5A (0.50) PLGPLAUHTR5AHTTCTSA
SCHEMBL9907997 0.83 HTR5A (0.53) PLGPLAUHTR5ALMNAMAPK1
SCHEMBL9909295 0.81 PLG (0.54) PLGPLAUHTR5ALMNAMAPK1
SCHEMBL9908010 0.81 HTR5A (0.49) PLGPLAUHTR5ACTSAMRGPRX4
SCHEMBL15500531 0.81 HTR5A (0.44) PLGPLAUHTR5ARAB9ATTR
SCHEMBL12875044 0.80 HTR5A (0.61) PLGPLAUHTR5ALMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E PLG 3328/4885PLAU 3322/4885HTR5A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.